An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
NCT03501615 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2020-06-29
Summary
Early Access Programme to provide treatment access to moxetumomab pasudotox for eligible patients with relapsed/refractory hairy cell leukemia
Conditions
- Relapsed/Refractory Hairy Cell Leukemia
Interventions
- DRUG
-
Moxetumomab Pasudotox
A recombinant conjugated immunotoxin composed of a disulfide-stabilized anti-CD22 Ig Fv genetically fused to a truncated form of Pseudomonas exotoxin, PE38
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Nai Shun (Nancy) Yao, MD · MedImmune LLC
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT01550185 ·Status: TERMINATED ·Phase: PHASE1
-
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01253447 ·Status: COMPLETED ·Phase: PHASE2
-
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
NCT06533761 ·Status: RECRUITING ·Phase: PHASE1
-
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
NCT01564784 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
NCT02282358 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
NCT01620216 ·Status: TERMINATED ·Phase: PHASE2
-
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
NCT02124746 ·Status: COMPLETED ·Phase: PHASE2
-
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT00475150 ·Status: COMPLETED ·Phase: PHASE2
-
PXD101 in Treating Patients With Acute Myeloid Leukemia
NCT00357032 ·Status: COMPLETED ·Phase: PHASE2
-
Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
NCT07071155 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT06497062 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
NCT03816319 ·Status: SUSPENDED ·Phase: PHASE1
-
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
NCT04668885 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT04155580 ·Status: TERMINATED ·Phase: PHASE1
-
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
NCT04872478 ·Status: RECRUITING ·Phase: PHASE1
-
Venetoclax After TKI to Target Persisting Stem Cells in CML
NCT05701215 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
NCT05363488 ·Status: COMPLETED
-
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
NCT00301938 ·Status: COMPLETED ·Phase: PHASE1
-
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT03194685 ·Status: COMPLETED ·Phase: PHASE1
-
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05673057 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation
NCT00030186 ·Status: COMPLETED ·Phase: PHASE2
-
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05703542 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
NCT05038800 ·Status: TERMINATED ·Phase: PHASE1
-
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
NCT00703300 ·Status: COMPLETED ·Phase: PHASE1
-
CPX-351 in Higher Risk Myelodysplastic Syndromes
NCT04273802 ·Status: COMPLETED ·Phase: PHASE1/PHASE2